Voyager Therapeutics (VYGR) Competitors $4.22 -0.04 (-0.94%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$4.34 +0.12 (+2.73%) As of 02/21/2025 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends VYGR vs. PHVS, AVBP, COGT, OCS, BCYC, DNA, IMNM, AVDL, CVAC, and CDMOShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Pharvaris (PHVS), ArriVent BioPharma (AVBP), Cogent Biosciences (COGT), Oculis (OCS), Bicycle Therapeutics (BCYC), Ginkgo Bioworks (DNA), Immunome (IMNM), Avadel Pharmaceuticals (AVDL), CureVac (CVAC), and Avid Bioservices (CDMO). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Pharvaris ArriVent BioPharma Cogent Biosciences Oculis Bicycle Therapeutics Ginkgo Bioworks Immunome Avadel Pharmaceuticals CureVac Avid Bioservices Voyager Therapeutics (NASDAQ:VYGR) and Pharvaris (NASDAQ:PHVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, community ranking, media sentiment, earnings, risk and institutional ownership. Which has more volatility & risk, VYGR or PHVS? Voyager Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Pharvaris has a beta of -3.08, indicating that its stock price is 408% less volatile than the S&P 500. Does the media favor VYGR or PHVS? In the previous week, Voyager Therapeutics had 10 more articles in the media than Pharvaris. MarketBeat recorded 10 mentions for Voyager Therapeutics and 0 mentions for Pharvaris. Pharvaris' average media sentiment score of 1.90 beat Voyager Therapeutics' score of 0.02 indicating that Pharvaris is being referred to more favorably in the news media. Company Overall Sentiment Voyager Therapeutics Neutral Pharvaris Very Positive Do analysts recommend VYGR or PHVS? Voyager Therapeutics presently has a consensus target price of $15.72, suggesting a potential upside of 272.42%. Pharvaris has a consensus target price of $40.50, suggesting a potential upside of 145.60%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Voyager Therapeutics is more favorable than Pharvaris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Pharvaris 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor VYGR or PHVS? Voyager Therapeutics received 359 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 67.75% of users gave Voyager Therapeutics an outperform vote while only 66.67% of users gave Pharvaris an outperform vote. CompanyUnderperformOutperformVoyager TherapeuticsOutperform Votes39567.75% Underperform Votes18832.25% PharvarisOutperform Votes3666.67% Underperform Votes1833.33% Is VYGR or PHVS more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Pharvaris' net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Pharvaris' return on equity.Company Net Margins Return on Equity Return on Assets Voyager Therapeutics15.80% 8.33% 6.15% Pharvaris N/A -38.52%-36.69% Which has higher valuation and earnings, VYGR or PHVS? Voyager Therapeutics has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVoyager Therapeutics$250.01M0.92$132.33M$0.715.94PharvarisN/AN/A-$109.18M-$2.80-5.89 Do institutionals and insiders believe in VYGR or PHVS? 48.0% of Voyager Therapeutics shares are owned by institutional investors. 4.5% of Voyager Therapeutics shares are owned by insiders. Comparatively, 11.8% of Pharvaris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryVoyager Therapeutics beats Pharvaris on 16 of the 18 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.54M$3.12B$5.78B$8.98BDividend YieldN/A1.57%4.78%3.85%P/E Ratio5.9430.1126.4618.82Price / Sales0.92412.67457.0180.76Price / Cash1.42183.5344.0437.47Price / Book0.793.567.634.64Net Income$132.33M-$71.72M$3.18B$245.69M7 Day Performance-0.24%-2.45%-1.82%-2.63%1 Month Performance-19.16%0.36%0.22%-2.37%1 Year Performance-44.76%-11.50%17.49%13.65% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics4.5275 of 5 stars$4.22-0.9%$15.72+272.4%-44.8%$230.54M$250.01M5.94100Upcoming EarningsNews CoveragePHVSPharvaris2.2188 of 5 stars$17.27-0.6%$40.50+134.5%-40.7%$903.05MN/A-6.1730Positive NewsAVBPArriVent BioPharma1.1963 of 5 stars$26.60-0.9%$37.40+40.6%+36.2%$896.34MN/A0.0040Positive NewsCOGTCogent Biosciences1.3906 of 5 stars$8.03-1.8%$14.33+78.5%-6.5%$886.99MN/A-3.2480Upcoming EarningsPositive NewsOCSOculis2.4826 of 5 stars$21.590.0%$28.80+33.4%+70.9%$874.40M$980,000.00-11.192BCYCBicycle Therapeutics2.84 of 5 stars$12.55+0.5%$33.25+164.9%-49.7%$866.58M$26.98M-3.81240DNAGinkgo Bioworks0.8579 of 5 stars$14.73+8.7%$4.58-68.9%N/A$846.38M$217.11M-1.131,218Upcoming EarningsNews CoverageGap UpIMNMImmunome2.9734 of 5 stars$10.40-0.3%$28.60+175.0%-56.7%$829.71M$14.02M-1.2840Positive NewsAVDLAvadel Pharmaceuticals3.9614 of 5 stars$8.61-4.2%$19.88+130.8%-33.7%$829.66M$27.96M-10.9070CVACCureVac4.0957 of 5 stars$3.65flat$10.00+174.0%-3.5%$817.16M$58.18M6.641,172News CoverageCDMOAvid Bioservices2.2405 of 5 stars$12.50+0.1%$12.25-2.0%+68.9%$799.18M$139.91M-5.23320High Trading Volume Related Companies and Tools Related Companies Pharvaris Alternatives ArriVent BioPharma Alternatives Cogent Biosciences Alternatives Oculis Alternatives Bicycle Therapeutics Alternatives Ginkgo Bioworks Alternatives Immunome Alternatives Avadel Pharmaceuticals Alternatives CureVac Alternatives Avid Bioservices Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VYGR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYGR Stock Alerts